Recro Pharma, Inc. (REPH) Downgraded by Zacks Investment Research
According to Zacks, “Recro Pharma, Inc. is a clinical stage specialty pharmaceutical company. It develops non-opioid therapeutics for the treatment of pain in the post-operative setting. The company is developing intranasal formulation of Dexmedetomidine (Dex) for the treatment of post-operative pain and cancer breakthrough pain; sublingual formulation of Dex for the treatment of chronic pain; and Fadolmidine (Fado), a product candidate to treat post-operative pain and neuropathic pain. Recro Pharma, Inc. is based in Malvern, Pennsylvania. “
A number of other equities research analysts have also recently weighed in on the company. Brean Capital assumed coverage on Recro Pharma in a research note on Monday, October 3rd. They issued a buy rating and a $21.00 price objective for the company. Aegis assumed coverage on Recro Pharma in a research note on Monday, November 14th. They set a buy rating and a $21.00 price target for the company. Roth Capital assumed coverage on Recro Pharma in a research note on Friday, September 16th. They set a buy rating and a $24.00 price target for the company. Piper Jaffray Companies assumed coverage on Recro Pharma in a research note on Monday, December 19th. They set an overweight rating and a $12.00 price target for the company. Finally, HC Wainwright restated a buy rating and set a $19.00 price target on shares of Recro Pharma in a research note on Tuesday, November 29th. One equities research analyst has rated the stock with a sell rating and six have given a buy rating to the stock. The stock has an average rating of Buy and a consensus target price of $18.11.
Shares of Recro Pharma (NASDAQ:REPH) opened at 7.50 on Friday. Recro Pharma has a 1-year low of $5.59 and a 1-year high of $12.50. The company has a 50-day moving average of $7.63 and a 200-day moving average of $8.27. The firm’s market cap is $91.22 million.
COPYRIGHT VIOLATION WARNING: This news story was reported by Watch List News and is owned by of Watch List News. If you are viewing this news story on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark legislation. The legal version of this news story can be read at http://www.watchlistnews.com/recro-pharma-inc-reph-downgraded-by-zacks-investment-research/1061148.html.
In other Recro Pharma news, major shareholder Healthcare Master Fun Broadfin acquired 650,000 shares of the business’s stock in a transaction on Tuesday, December 13th. The stock was purchased at an average price of $6.00 per share, for a total transaction of $3,900,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 39.30% of the company’s stock.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in REPH. Northern Trust Corp acquired a new position in Recro Pharma during the third quarter valued at about $128,000. BlackRock Fund Advisors boosted its position in Recro Pharma by 37.5% in the second quarter. BlackRock Fund Advisors now owns 15,268 shares of the specialty pharmaceutical company’s stock valued at $121,000 after buying an additional 4,163 shares during the last quarter. Acadian Asset Management LLC acquired a new position in Recro Pharma during the third quarter valued at about $140,000. Wells Fargo & Company MN boosted its position in Recro Pharma by 56.0% in the third quarter. Wells Fargo & Company MN now owns 31,200 shares of the specialty pharmaceutical company’s stock valued at $276,000 after buying an additional 11,200 shares during the last quarter. Finally, BlackRock Institutional Trust Company N.A. boosted its position in Recro Pharma by 30.5% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 49,947 shares of the specialty pharmaceutical company’s stock valued at $397,000 after buying an additional 11,682 shares during the last quarter. Hedge funds and other institutional investors own 51.43% of the company’s stock.
Recro Pharma Company Profile
Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Recro Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.